

Biocon nears full integration of biologics business after Mylan buyback
Subscribe to enjoy similar stories. MUMBAI : Biocon Ltd is close to completing the integration of its subsidiary Biocon Biologics Ltd (BBL) with itself, after making progress last quarter on buying back the minority stake, Biocon Biologics' chief executive officer (CEO) Shreehas Tambe said on Friday. The Bengaluru-based company on 14 January said it raised ₹4,150 crore ($460 million) through a qualified institutional placement (QIP) of shares to buy out Mylan Inc’s (Viatris) stake in the subsidiary.
Days later, it announced it had completed the acquisition of the remaining equity shares of BBL from Mylan for a cash consideration of $200 million, raising its stake to over 98%. Biocon's board on Thursday granted in-principle approval to acquire the remaining 2% stake in BBL from employees who hold or will hold BBL's shares pursuant to exercise of stock options, and other minority shareholders. “The businesses are in the process of getting together, and by the end of this quarter, which is ending March 31st 2026, we will be completing the integration process and will migrate towards one Biocon," Tambe told Mint in an interview.
In June, Biocon raised its stake in BBL from 71% to 79% after settling structured debt instruments. In December, it announced the full integration of the subsidiary following months of deliberations over a potential listing or merger. The deal, which valued BBL at $5.5 billion, was described by Biocon as the most value-accretive option.
Read on livemint.com